Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation.
about
Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancerExtended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.Low cost abiraterone.Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care.Recent advances in "smart" delivery systems for extended drug release in cancer therapy
P2860
Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Leuprolide acetate 1-, 3- and ...... eview and economic evaluation.
@en
type
label
Leuprolide acetate 1-, 3- and ...... eview and economic evaluation.
@en
prefLabel
Leuprolide acetate 1-, 3- and ...... eview and economic evaluation.
@en
P2093
P2860
P356
P1476
Leuprolide acetate 1-, 3- and ...... eview and economic evaluation.
@en
P2093
Ahmed M Abou-Setta
Bertrand Tombal
Isaac Odeyemi
Manpreet Sidhu
Peny Retsa
P2860
P304
P356
10.2147/CEOR.S44855
P407
P577
2013-06-24T00:00:00Z